WATERTOWN, MA – April 13, 2015 – Blend Therapeutics, Inc., a biopharmaceutical company discovering and developing two distinct classes of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers, announced today the appointment of Drew Fromkin as President and Chief Executive Officer and a member of the company’s Board of Directors. Mr. Fromkin previously served as President and Chief Executive Officer of Clinical Data, Inc., until its acquisition by Forest Laboratories. He is an accomplished, global healthcare leader with more than 25 years of experience leading private and public life sciences and healthcare services companies through all stages of growth, including product development and commercial operations.
“We are very excited to work with Drew who is a highly strategic, energetic and visionary executive to build Blend into an important oncology company on a path to bringing innovative cancer treatments to patients,” said Omid Farokhzad, MD, Founder and Chairman of Blend Therapeutics and Associate Professor at Harvard Medical School.
“Drew’s exceptional track record of leadership and operational expertise, as well as strong product and corporate development background, will serve Blend well as the company embarks on the next stage of its growth with two product candidates entering clinic over the next twelve months,” added James Barrett, PhD, Founding Investor of Blend Therapeutics and General Partner at New Enterprise Associates.